Related Experiment Video
Updated: Oct 17, 2026
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome
Insights
Intravenous immunoglobulin (IVIG) significantly speeds recovery in children with Guillain-Barré syndrome (GBS). A shorter 2-day IVIG course showed faster improvement than a 5-day course or supportive care alone.
Area of Science:
- Pediatric Neurology
- Immunology
Background:
- Guillain-Barré syndrome (GBS) is a rare autoimmune disorder affecting children.
- Effective treatments are crucial for improving outcomes in pediatric GBS.
Purpose of the Study:
- To evaluate the efficacy of intravenous immunoglobulin (IVIG) in treating pediatric Guillain-Barré syndrome.
- To compare different IVIG dosing regimens and their impact on recovery rates.
Main Methods:
- Retrospective review of 75 children diagnosed with GBS across two centers (Ankara, Turkey, and Toronto, Canada).
- Patients were divided into three groups: IVIG (2-day course), IVIG (5-day course), and supportive care only.
- Comparison of functional grades, bulbar signs, and autonomic dysfunction between groups.
Main Results:
- IVIG treatment significantly accelerated recovery compared to supportive care alone.
- Patients receiving IVIG showed a faster improvement in functional grades (17.4-20.8 days vs. 62.4 days).
- A 2-day IVIG course demonstrated a faster rate of recovery than a 5-day course.
Conclusions:
- Intravenous immunoglobulin (IVIG) is an effective treatment for pediatric Guillain-Barré syndrome.
- Shorter, intensive IVIG regimens (2-day course) may offer faster recovery benefits.
Abstract:
We have retrospectively reviewed the data of 75 consecutive children diagnosed with Guillain-Barré syndrome (GBS) and hospitalized in two centres. There were 51 children with GBS treated in Ankara, Turkey and 24 patients treated in Toronto, Canada. To evaluate the effect of intravenous immunoglobulin (IVIG) treatment, the patients were divided into three groups. All 24 Canadian patients received IVIG in a dose of 1 g/kg/day for 2 days. In the Ankara group 23 children received 0.4 g/kg/day for 5 days and the remaining 28 patients in that group received supportive treatment only. In all but two patients IVIG was started within the first 2 weeks of neuropathic symptoms. The patients' data, including mean functional grades, frequency of bulbar signs and autonomic dysfunction and age were similar in all three groups. Analysis of the short-term outcome demonstrated that the patients treated with IVIG had a significantly faster rate of recovery. Mean time-lapse until improvement of one functional grade was 17.4 days in the IVIG group from Toronto, and 20.8 days in the IVIG group and 62.4 days in the non-IVIG group of patients from Ankara. We conclude that IVIG has considerable efficacy in the treatment of children with GBS. Furthermore, we have also demonstrated a faster rate of recovery in patients who received a total dose of IVIG in 2 days as opposed to 5 days.
